LCG
CSTL icon

Lisanti Capital Growth’s Castle Biosciences CSTL Stock Holding History

Lisanti Capital Growth’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-46,265
Closed -$1.23M – 121
2024
Q4 		$1.23M Sell
46,265
-108,445
-70% -$3.3M 0.3% 96
2024
Q3 		$4.41M Buy
154,710
+58,160
+60% +$1.48M 1.12% 36
2024
Q2 		$2.1M Buy
+96,550
New +$2.15M 0.51% 76
2021
Q4 		– Sell
-35,855
Closed -$2.38M – 125
2021
Q3 		$2.38M Sell
35,855
-71,795
-67% -$5.05M 0.35% 101
2021
Q2 		$7.89M Buy
107,650
+50,470
+88% +$3.33M 0.98% 34
2021
Q1 		$3.92M Buy
+57,180
New +$4.3M 0.5% 82

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Lisanti Capital Growth's CSTL Position: Q1 2025 in Review

Lisanti Capital Growth sold out of Castle Biosciences (CSTL) in Q1 2025, closing a stake of 46,265 shares — an estimated $1.23M sold.

Lisanti Capital Growth first reported a position in CSTL in Q1 2021 and held it in 6 quarters. The position peaked at $7.89M in Q2 2021. 180 funds tracked by Wall St. Rank hold CSTL as of Q1 2025.

  • Lisanti Capital Growth reported no remaining Castle Biosciences position as of Q1 2025 after selling out during the quarter.
  • Lisanti Capital Growth sold 46,265 Castle Biosciences shares in Q1 2025, an estimated $1.23M.
  • Lisanti Capital Growth first reported a position in Castle Biosciences in Q1 2021 and held it in 6 quarters.
  • Lisanti Capital Growth's Castle Biosciences position peaked at $7.89M in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2025.

Based on Lisanti Capital Growth's 13F filing for Q1 2025, filed 25 Apr 2025.